Baker Hughes Inc. (NYSE: BKR): Though Goldman Sachs lowered the price target on the oil services giant to $26 from $29, it kept a Buy rating on the shares. The consensus target is $27.90. The last trade on Friday was reported at $21.24 a share.
Bloomin’ Brands Inc. (NASDAQ: BLMN): Deutsche Bank raised the stock to Hold from Buy and has a $34 price target. The consensus target is right in line at $34.77. The closing trade for Friday was reported at $25.13.
Cano Health Inc. (NASDAQ: CANO): Credit Suisse started coverage with an Outperform rating and an $18 price target. The consensus target is $22, and the shares were last seen at $10.75 on Friday.
ChargePoint Holdings Inc. (NASDAQ: CHPT): Goldman Sachs started coverage with a Neutral rating and a $24 price target. The consensus target is much higher at $37.50. The shares ended trading on Friday at $23.65.
Doma Holdings Inc. (NASDAQ: DOMA): JMP Securities initiated coverage with a Buy rating and a $14 price target. No consensus target for the stock was available. The shares closed at $6.84 on Friday.
DoorDash Inc. (NYSE: DASH): Gordon Haslet started the food delivery giant with a Buy rating and a $206 price target. That compares with the $175.47 consensus target and Friday’s closing trade of $174.29.
Estee Lauder Companies Inc. (NYSE: EL): Deutsche Bank downgraded the fragrance and makeup giant to Hold from Buy but slightly raised the price target to $322 from $320. The consensus target is $336.81, and the final trade on Friday came in at $333.83.
First Solar Inc. (NASDAQ: FSLR): Susquehanna raised the stock to Positive from Neutral and lifted the $89 price target to $120. The consensus target is just $86.90. The shares closed Friday at $86.04, which was up almost 3% on the day, and they were up an additional 3% in premarket trading.
Hilton Grand Vacations Inc. (NYSE: HGV): Zacks says the Delta variant is throwing a wrench into vacation plans around the world, and so it has named this as its Bear of the Day stock. The shares ended last week trading at $40.67 apiece and have a consensus analyst target of $49.50.
Infinity Pharmaceutical Inc. (NASDAQ: INFI): JPMorgan raised its Neutral rating to Overweight with a $6 price target. The consensus target is up at $8.50. Friday’s last trade came in at $2.12. The shares were up over 16% in the premarket, and this was one of our top stocks to buy under $10 this past weekend.